| Wish You Were an Early Investor in NVIDIA? Microsoft? Or Apple? Keep reading if so... (ad) |
|
| Tesla's latest crash shells out nine consecutive winners (ad) |
Most Tesla Shareholders are disappointed in the stock's performance in 2024.
Year to date, it's down 30%...
And things don't seem to be getting better.
That said, one professional trader has found a way to turn Tesla's demise into a flurry of opportunity…
In fact, he has not lost a single trade on Tesla this year.
As of this mailing he's 9 for 9 with incredible wins under his belt.
Just see for yourself.
But I can promise that you'll see all the details for yourself here. |
|
 Apple Inc. (AAPL)    Amazon.com, Inc. (AMZN)   Barker Minerals Ltd (BML) - No Headlines, Ratings, Earnings Results, Dividends, Insider Trades, Options Activity, Company Press Releases or Headlines Today
 Meta Platforms, Inc. (META)  - CEO Mark Zuckerberg sold 16,702 shares of the company's stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $510.88, for a total transaction of $8,532,717.76. Following the transaction, the chief executive officer now owns 230,461 shares in the company, valued at $117,737,915.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
- CEO Mark Zuckerberg sold 9,760 shares of the company's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $502.87, for a total value of $4,908,011.20. Following the sale, the chief executive officer now owns 247,915 shares in the company, valued at approximately $124,669,016.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
- (6/27) Meta Platforms, Inc. (NASDAQ:META) is DGS Capital Management LLC's 7th Largest Position (marketbeat.com)
- (6/27) Insider Selling: Meta Platforms, Inc. (NASDAQ:META) CEO Sells 9,760 Shares of Stock (insidertrades.com)
- (6/27) Here Is My Top Artificial Intelligence (AI) Stock to Buy Right Now (Hint: It's Not Nvidia) (fool.com)
- (6/27) The 3 Smartest Social Media Stocks to Buy With $500 Right Now (investorplace.com)
- (6/26) Rezny Wealth Management Inc. Invests $1.26 Million in Meta Platforms, Inc. (NASDAQ:META) (marketbeat.com)
- (6/26) 'My mother is being catfished': She fell 'madly in love' with a man over Facebook. How do I convince her that it's a scam? (marketwatch.com)
- (6/26) Gate.io CEO Dr. Han at Seoul Meta Week 2024: Building Trust as the Foundation for Blockchain Advancement (newsfilecorp.com)
- (6/26) 3 Stocks to Buy and Hold Onto for Dear Life (investorplace.com)
- (6/26) Emplifi Data Shows Airlines Are More Likely to Respond to Customer Questions on Instagram Than on Facebook or X (businesswire.com)
 Microsoft Co. (MSFT)  - BlackBerry (NYSE:BB) was upgraded by analysts at CIBC from a "neutral" rating to a "sector outperform" rating.The current price is $2.50.
- Bank of New York Mellon (NYSE:BK) was upgraded by analysts at Keefe, Bruyette & Woods from a "market perform" rating to an "outperform" rating. They now have a $70.00 price target on the stock, up previously from $60.00. This represents a 17.9% upside from the current price of $59.37.
- Canadian National Railway (NYSE:CNI) (TSE:CNR) was upgraded by analysts at National Bank Financial from a "sector perform" rating to an "outperform" rating.The current price is $119.39.
- Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $17.90 price target on the stock, up previously from $16.80. This represents a 24.7% upside from the current price of $14.36.
- Qiagen (NYSE:QGEN) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $50.00 price target on the stock. This represents a 21.1% upside from the current price of $41.28.
- View today's most recent analysts' upgrades at MarketBeat.com
| "Trump Loophole" Beats Inflation? (ad) |
Central Bank Gold Heist In Progress
Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
Click here to get your free copy today. |
|
- Agilent Technologies (NYSE:A) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.The current price is $132.22.
- Rio Tinto Group (NYSE:RIO) was downgraded by analysts at Berenberg Bank from a "buy" rating to a "hold" rating.The current price is $65.89.
- U.S. Bancorp (NYSE:USB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $43.50 price target on the stock. This represents a 10.0% upside from the current price of $39.53.
- View today's most recent analysts' downgrades at MarketBeat.com
| 2024's Must-Watch Stocks! (ad) |
Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
[Unlock Your Report Now] |
|
- ACADIA Pharmaceuticals (NASDAQ:ACAD) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $31.00 price target on the stock. This represents a 92.0% upside from the current price of $16.15.
- Altus Midstream (NASDAQ:ALTM) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $4.30 price target on the stock. This represents a 20.1% upside from the current price of $3.58.
- BWX Technologies (NYSE:BWXT) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating and a $113.00 price target on the stock. This represents a 18.1% upside from the current price of $95.65.
- Calidi Biotherapeutics (NYSEAMERICAN:CLDI) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $1.00 price target on the stock. This represents a 393.6% upside from the current price of $0.20.
- CompoSecure (NASDAQ:CMPO) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $12.00 price target on the stock. This represents a 82.1% upside from the current price of $6.59.
- CARGO Therapeutics (NASDAQ:CRGX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $37.00 price target on the stock. This represents a 144.7% upside from the current price of $15.12.
- Crescent Energy (NYSE:CRGY) is now covered by analysts at KeyCorp. They set an "overweight" rating and a $16.00 price target on the stock. This represents a 36.3% upside from the current price of $11.74.
- Denison Mines (NYSEAMERICAN:DNN) (TSE:DML) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $2.60 price target on the stock. This represents a 25.6% upside from the current price of $2.07.
- Dianthus Therapeutics (NASDAQ:DNTH) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.The current price is $25.64.
- Dynatrace (NYSE:DT) is now covered by analysts at Piper Sandler. They set a "neutral" rating and a $50.00 price target on the stock. This represents a 13.9% upside from the current price of $43.91.
- Exact Sciences (NASDAQ:EXAS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $70.00 price target on the stock. This represents a 59.8% upside from the current price of $43.81.
- Grab (NASDAQ:GRAB) is now covered by analysts at Mizuho. They set an "outperform" rating and a $5.00 price target on the stock. This represents a 41.2% upside from the current price of $3.54.
- Hologic (NASDAQ:HOLX) is now covered by analysts at Stephens. They set an "overweight" rating and a $87.00 price target on the stock. This represents a 19.5% upside from the current price of $72.78.
- Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $86.00 price target on the stock. This represents a 286.0% upside from the current price of $22.28.
- Kyndryl (NYSE:KD) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $33.00 price target on the stock. This represents a 26.5% upside from the current price of $26.09.
- Myriad Genetics (NASDAQ:MYGN) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $29.00 price target on the stock. This represents a 17.9% upside from the current price of $24.59.
- Nautilus Biotechnology (NASDAQ:NAUT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $6.00 price target on the stock. This represents a 160.9% upside from the current price of $2.30.
- Neurogene (NASDAQ:NGNE) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $65.00 price target on the stock. This represents a 86.0% upside from the current price of $34.94.
- PagerDuty (NYSE:PD) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating and a $24.00 price target on the stock. This represents a 7.0% upside from the current price of $22.44.
- SOPHiA GENETICS (NASDAQ:SOPH) is now covered by analysts at Guggenheim. They set a "buy" rating and a $6.00 price target on the stock. This represents a 33.0% upside from the current price of $4.51.
- Taysha Gene Therapies (NASDAQ:TSHA) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $5.00 price target on the stock. This represents a 135.8% upside from the current price of $2.12.
- Viking Therapeutics (NASDAQ:VKTX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $105.00 price target on the stock. This represents a 116.1% upside from the current price of $48.58.
- Vertex Pharmaceuticals (NASDAQ:VRTX) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $545.00 price target on the stock. This represents a 14.2% upside from the current price of $477.16.
- View today's most recent analysts' new coverage at MarketBeat.com
| Get 30 Days of MarketBeat All Access Free | | Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: |
| - Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. - Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. - Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
| START YOUR 30-DAY FREE TRIAL  |
|
| Upgrade Your Subscription |
Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. | UPGRADE NOW |
|
View and add up to five holdings to your watchlist.
| VIEW MY PORTFOLIO |
|
Join MarketBeat's free stock discussion and trading idea group on Facebook.
| JOIN NOW |
|
Thank you for subscribing to MarketBeat! We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com. If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails. © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103 . United States. Today's Bonus Content: Elon's New Device is About to Shock the World |
|
No comments:
Post a Comment